『Episode 41: The Estrogen Lie, Revisited』のカバーアート

Episode 41: The Estrogen Lie, Revisited

Episode 41: The Estrogen Lie, Revisited

無料で聴く

ポッドキャストの詳細を見る

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
Back in Episode 20, Dr. Jill and Dr. Ade covered the FDA's decision to walk back twenty years of black box warnings on hormone therapy. Since then, hormone therapy has become a genuine moment on social media, and not always an accurate one. In this quick-turnaround update, they separate what the newest research actually shows from what the internet is claiming, including a new Stanford study linking estrogen-only therapy to lower Alzheimer's markers, why that finding does not extend to combined therapy, and what the twenty-year-old dementia data really pins the risk on.Segment GuideCold open: What changed since Episode 20, and why this update existsThe quick WHI recap, done right: relative risk versus absolute risk, and the age-stratified "timing hypothesis"What the FDA actually changed, and when: the November 2025 label update, and what stayed in placeWhat's actually prescribed now versus what WHI tested: bioidentical estradiol and micronized progesterone versus the oral synthetic combination used in the original trial, including how the two progestogens differ at the receptor levelThe hype swing of 2026: what hormone therapy is well-supported for, and what it is notThe new Stanford Alzheimer's study: what its three parts can and cannot tell us, and why the dementia-risk signal from 2003 traces to one specific drug, not to progesterone as a categoryWhat we'd actually tell a patient: an honest, evidence-based bottom lineKey TakeawaysThe WHI's real numbers are absolute, not relative: about 8 additional breast cancer cases per 10,000 women per year in the combined-therapy arm, not the large-sounding relative-risk percentage that made headlines in 2002.Estrogen-alone therapy showed fewer breast cancer cases in the WHI, a reduction that reached statistical significance in longer-term follow-up along with a reduction in breast cancer mortality.Today's typical prescription, transdermal estradiol with micronized progesterone, is a different drug, different route, and different population than what the original WHI tested.A new Stanford study (Neurology, August 2026) found estrogen-only hormone therapy associated with a roughly 35 percent lower likelihood of Alzheimer's pathology markers on autopsy, plus supporting signals in dementia diagnoses and biomarkers. It is observational, not a randomized trial, and it could not address combined therapy either way due to sample size.The dementia-risk signal from the 2003 WHI Memory Study traces specifically to oral conjugated equine estrogen plus medroxyprogesterone acetate, not to progesterone or progestins as a category. Whether the micronized progesterone used today carries the same risk is a genuinely open question, not a settled no.Formulation matters. Ask your provider exactly what you are being prescribed, oral versus transdermal estrogen, and bioidentical micronized progesterone versus a synthetic progestin.Research and Sources MentionedHHS: Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement TherapyNPR, August 7, 2026: Everyone's talking about hormone therapy for menopause. Should I be on it?STAT News, January 8, 2026: Hormone therapy for menopause is being overhyped, againStanford Medicine, August 2026: Study ties estrogen-based menopausal hormone therapy to lower Alzheimer's riskNational Cancer Institute: Menopausal Estrogen Therapy Benefits and Risks Vary by Age (WHI analysis)International Menopause Society: Lessons from KEEPS, the Kronos Early Estrogen Prevention StudyShumaker et al., JAMA, 2003: Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment (WHI Memory Study)Barth et al., Lancet Diabetes & Endocrinology, 2023: Sex Steroids and the Female Brain Across the LifespanVinogradova et al., BMJ, 2021: Use of menopausal hormone therapy and risk of dementia (UK QResearch/CPRD cohort)Savolainen-Peltonen et al., BMJ, 2019: Use of Postmenopausal Hormone Therapy and Risk of Alzheimer's Disease in FinlandGleason et al., PLOS Medicine, 2015: Effects of Hormone Therapy on Cognition and Mood (KEEPS-Cognitive and Affective Study)A Note on This EpisodeThis episode is for educational purposes and reflects Dr. Jill and Dr. Ade's read of the current evidence. It is not personalized medical advice. Hormone therapy decisions depend on individual history, and listeners should talk with their own healthcare provider before starting, stopping, or changing any hormone therapy.Connect With UsHave a question about your own hormone therapy, or a topic you want us to cover? Email connect@modernmidlifecollective.com or visit www.modernmidlifecollective.com for links to everything mentioned in this episode.If this episode was useful, follow or subscribe wherever you listen, and consider leaving a rating and review. It genuinely helps other midlife women find the show.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません